ideasIdea
A national late-effects registry linking treatment exposures to outcomes decades later
We know surprisingly little about what happens to cancer survivors twenty years on. Linking their treatment records to later health records would show which treatments cause which problems and who needs watching.
Childhood cancer survivor cohorts (CCSS in the US, BCCSS in the UK, DCOG-LATER in the Netherlands) transformed understanding of late effects. Adult survivors have no equivalent at scale. A national registry linking cancer registry treatment data (including radiotherapy doses and cumulative drug doses) to hospital, prescribing, and mortality records would generate late-effect risks for modern therapies, including immunotherapy and targeted agents, whose long-term effects are unknown.
Hypothesis
Within five years, linked registry data will quantify late cardiovascular, endocrine, and second-cancer risks for at least ten contemporary regimens with sufficient precision to change surveillance guidelines.
Rationale
Nordic and Dutch linkage studies show that registry linkage yields robust late-effect estimates at low cost relative to cohort studies.
What would test it
Establish linkage in one country with strong registries, publish first risk estimates within three years, and track adoption into surveillance guidelines.
Maturity
early clinical
Who has to act
data
Cost to try
Medium ($1M to $50M)
Years to first evidence
5
Bottlenecks it attacks
- Survivorship and late effects are neglected · Tens of millions of people live after cancer with heart damage, infertility, second cancers and fear, and few services.
- Weak real-world evidence and registries · We do not reliably know what happens to patients after approval, so we cannot tell which drugs deliver in practice.
- Data silos · Records, scans, genomes and outcomes sit in separate systems that cannot talk. Every patient's experience is lost to the next.